Despite considerable advances in early diagnosis, prostate cancer (PCa) remains the second leading cause of cancer-related deaths in men in western countries. In fact, although efficient therapies exist for early-stage disease, the treatment of advanced PCa remains unsuccessful mainly due to its poor responsiveness to anti-cancer agents. This evidence underlines the urgent need for the development of novel and more effective therapeutic approaches. In this context, the documented dysregulation of microRNAs (miRNAs) -which are short non-coding RNAs that regulate gene expression at post-transcriptional level-in PCa, together with their potential to simultaneously regulate multiple oncogenic/tumor-suppressive pathways, has stimulated interest in defining a functional association between altered expression of specific miRNAs and the response of PCa to anti-cancer agents. The purpose of this review is to provide an overview on PCa-related miRNAs as potential novel therapeutic targets/tools, with a special focus on the role that they may play in conditioning the responsiveness of PCa to anti-cancer drugs.
|Titolo:||MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs|
|Settore Scientifico Disciplinare:||Settore BIO/11 - Biologia Molecolare|
Settore MED/04 - Patologia Generale
Settore BIO/13 - Biologia Applicata
|Data di pubblicazione:||2016|
|Digital Object Identifier (DOI):||10.2174/1389450116666150316223341|
|Appare nelle tipologie:||01 - Articolo su periodico|